Category: PharmaceuticalsSyndicate content

TCT 2014 Roundup

September 15, 2014 by Brad Perriello

A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.

TCT 2014 Roundup

Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:

Baxter names its pharma spinout: Baxalta

September 11, 2014 by Arezu Sarvestani

Baxter's has 'high' hopes for its coming Baxalta spinout, which will get a full visual work-up before the company goes live mid-2015.

Baxter names its pharma spinout: Baxalta

Baxter (NYSE:BAX) crept a little closer to spinning out its biopharmaceuticals division into an independent entity by giving the company a name: Baxalta.

Allergan caves to shareholder meeting after Valeant, Ackman rally support

September 9, 2014 by Arezu Sarvestani

Allergan confirmed late last week that it would call the shareholder meeting demanded by unsolicited buyers Valeant Pharmaceuticals and activist investor William Ackman.

Allergan caves to shareholder meeting after Valeant, Ackman rally support

Valeant sues Allergan for special meeting after show of shareholder support

August 25, 2014 by Arezu Sarvestani

Valeant Pharmaceuticals files a lawsuit aiming to force Allergan to hold a special shareholder meeting after hand-delivering 1,500 pages of documents showing shareholder support.

Valeant files new lawsuit in Allergan acquisition saga

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Allergan can't delay shareholder vote on hostile Valeant bid

August 22, 2014 by Brad Perriello

Valeant Pharmaceuticals and Pershing Square Capital Management reportedly plan to ask Allergan for a shareholder vote on their hostile takeover attempt, after a federal judge rules that Allergan's insider trading lawsuit won't delay the meeting.

Allergan can't delay shareholder vote on hostile Valeant bid

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Report: Allergan solicits Salix in bid to stymie hostile Valeant takeover

August 20, 2014 by Brad Perriello

Allergan reportedly solicits Salix Pharmaceuticals in a bid to stymie the $53 billion hostile takeover move by Valeant Pharmaceuticals and Pershing Square Capital Management.

Report: Allergan solicits Salix in bid to thwart hostile Valeant takeover

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO

August 14, 2014 by Brad Perriello

The U.S. Securities & Exchange Commission is launching an insider trading probe into the hostile takeover bid for Allergan by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital, even as Allergan inks a $588 million deal for Taris Biomedical's Liris bladder drug and Ackman dangles the prospect of an IPO for Pershing Square.

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles Pershing IPO
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp